First‐Generation HIV‐1 Protease Inhibitors for the Treatment of HIV/AIDS

[1]  Heinrich Sticht,et al.  Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance. , 2005, Journal of chemical theory and computation.

[2]  G. Marshall,et al.  Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. , 1991, Journal of medicinal chemistry.

[3]  A. Haight,et al.  An Efficient Stereocontrolled Strategy for the Synthesis of Hydroxyethylene Dipeptide Isosteres , 1994 .

[4]  A Wlodawer,et al.  Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. , 1991, Biochemistry.

[5]  L. Tong,et al.  Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. , 1997, Journal of medicinal chemistry.

[6]  K. Appelt,et al.  Structure-based drug design of nonpeptidic P2 substituents for HIV-1 protease inhibitors , 1995 .

[7]  A. Freeman,et al.  Studies toward the Large-Scale Synthesis of the HIV Proteinase Inhibitor Ro 31-8959 , 1994 .

[8]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[9]  C. Schiffer,et al.  Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. , 2002, Structure.

[10]  E. Freire,et al.  Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. , 2003, Biochemistry.

[11]  P. Colman.  New antivirals and drug resistance. , 2009, Annual review of biochemistry.

[12]  Arun K. Ghosh,et al.  Development of protease inhibitors and the fight with drug-resistant HIV-1 variants. , 2008, Advances in pharmacology.

[13]  C. Supuran,et al.  Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. , 2007, Current medicinal chemistry.

[14]  E A Emini,et al.  3-Tetrahydrofuran and pyran urethanes as high-affinity P2-ligands for HIV-1 protease inhibitors. , 1993, Journal of medicinal chemistry.

[15]  Tomi K. Sawyer,et al.  A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. , 1990, Disease markers.

[16]  M. Katharine Holloway,et al.  X-Ray Crystal Structure of the HIV Protease Complex with L-700,417, an Inhibitor with Pseudo C2 Symmetry , 1991 .

[17]  W. M. Sanders,et al.  L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. , 1991, Journal of medicinal chemistry.

[18]  R. Dixon,et al.  Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution. , 1991, The Journal of biological chemistry.

[19]  B. Sadler,et al.  In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. , 1996, Antiviral research.

[20]  A Wlodawer,et al.  Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. , 1989, Science.

[21]  C. Petropoulos,et al.  Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. , 2000, The Journal of infectious diseases.

[22]  Ann Thayer.  NEW ANTIRETROVIRALS: In recent years, new drugs have brought better options for CONTROLLING HIV , 2008 .

[23]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[24]  P A Kollman,et al.  Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease. , 1991, Journal of medicinal chemistry.

[25]  M. Hosur,et al.  Observation of a tetrahedral reaction intermediate in the HIV-1 protease-substrate complex. , 2005, The Biochemical journal.

[26]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Ho,et al.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.

[28]  Ann Thayer.  REACHING COMMON GROUND, GLOBALLY , 2008 .

[29]  G R Marshall,et al.  Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. , 1990, Journal of medicinal chemistry.

[30]  A Wlodawer,et al.  X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Arun K. Ghosh,et al.  Syntheses of FDA Approved HIV Protease Inhibitors. , 2002, Synthesis.

[32]  K. Rossen,et al.  Highly diastereoselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524 , 1994 .

[33]  J. Plattner,et al.  A synthesis of protected aminoalkyl epoxides from .alpha.-amino acids , 1987 .

[34]  Brian W. Metcalf,et al.  Human immunodeficiency virus protease: A target for aids therapy , 1990 .

[35]  Wei Zhang,et al.  Highly enantioselective epoxidation catalysts derived from 1,2-diaminocyclohexane , 1991 .

[36]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[37]  A. Wissner.  2-Heterosubstituted silylated ketone acetals: reagents for the preparation of .alpha.-functionalized methylketones from carboxylic acid chlorides , 1979 .

[38]  M. Murcko,et al.  Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .

[39]  L. Kuo,et al.  Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. , 1996, The Journal of biological chemistry.

[40]  T L Blundell,et al.  On the rational design of renin inhibitors: X-ray studies of aspartic proteinases complexed with transition-state analogues. , 1987, Biochemistry.

[41]  K. Appelt,et al.  A systematic study of P1–P3 spanning sidechains for the inhibition of HIV-1 protease , 1995 .

[42]  Irene T Weber,et al.  Caught in the Act: the 1.5 A resolution crystal structures of the HIV-1 protease and the I54V mutant reveal a tetrahedral reaction intermediate. , 2007, Biochemistry.

[43]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[44]  David L. Beveridge,et al.  Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation , 1993 .

[45]  R. DesJarlais,et al.  An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis. , 1994, Biochemistry.

[46]  S. Gulnik,et al.  Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. , 1995, Biochemistry.

[47]  J F Davies,et al.  Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. , 1997, Journal of medicinal chemistry.

[48]  J L Meek,et al.  Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. , 1996, Chemistry & biology.

[49]  A. Molla,et al.  Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. , 1998, Journal of medicinal chemistry.

[50]  P. Darke,et al.  Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design. , 1992, Journal of Medicinal Chemistry.

[51]  M. Jaskólski,et al.  Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. , 1989, Science.

[52]  C. Senanayake,et al.  The role of 4-(3-phenylpropyl)pyridine N-Oxide (P3NO) in the manganese-salen-catalyzed asymmetric epoxidation of indene , 1996 .

[53]  Masayuki Hata,et al.  Computational simulations of HIV-1 proteases--multi-drug resistance due to nonactive site mutation L90M. , 2006, Journal of the American Chemical Society.

[54]  S. Vasavanonda,et al.  Evaluation of substituted benzamides as P2 ligands for symmetry-based inhibitors of HIV protease , 1995 .

[55]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[56]  J. Craig,et al.  Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. , 1998, AIDS.

[57]  Ursula Rothlisberger,et al.  Drug resistance in HIV‐1 protease: Flexibility‐assisted mechanism of compensatory mutations , 2002, Protein science : a publication of the Protein Society.

[58]  M. Hatada,et al.  Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. , 1991, Journal of medicinal chemistry.

[59]  D. R. Kuritzkes,et al.  Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.

[60]  J. Huff,et al.  HIV protease: a novel chemotherapeutic target for AIDS. , 1991, Journal of medicinal chemistry.

[61]  M. Markowitz,et al.  Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.

[62]  H. Hilpert,et al.  Synthesis of the HIV-Proteinase Inhibitor Saquinavir: A Challenge for Process Research , 1996, CHIMIA.

[63]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[64]  Y. Tsantrizos.  Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus. , 2008, Accounts of chemical research.

[65]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[66]  J. Martin,et al.  Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease. , 1999, Biochemistry.

[67]  A Tropsha,et al.  Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state. , 1995, Journal of medicinal chemistry.

[68]  H. B. Schock,et al.  Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials , 1996, The Journal of Biological Chemistry.

[69]  A. W. Douglas,et al.  The behavior of indene oxide in the ritter reaction: A simple route to cis-aminoindanol , 1995 .

[70]  W. Howe,et al.  Inhibitors of the protease from human immunodeficiency virus: design and modeling of a compound containing a dihydroxyethylene isostere insert with high binding affinity and effective antiviral activity. , 1991, Journal of medicinal chemistry.

[71]  P. Darke,et al.  The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors. , 1994, Journal of medicinal chemistry.

[72]  John P. Overington,et al.  X-ray analysis of HIV-1 proteinase at 2.7 Å resolution confirms structural homology among retroviral enzymes , 1989, Nature.

[73]  Dale J. Kempf,et al.  Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease , 1994 .

[74]  Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors. , 1993, Journal of medicinal chemistry.

[75]  Peter V Coveney,et al.  Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases. , 2008, Journal of the American Chemical Society.

[76]  M. Doyle,et al.  Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity. , 1996, Biochemistry.

[77]  J. Hašek,et al.  Hydroxyethylamine isostere of an HIV-1 protease inhibitor prefers its amine to the hydroxy group in binding to catalytic aspartates. A synchrotron study of HIV-1 protease in complex with a peptidomimetic inhibitor. , 2002, Journal of medicinal chemistry.

[78]  J. Ermolieff,et al.  Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. , 1997, Biochemistry.

[79]  B. E. Evans,et al.  A stereocontrolled synthesis of hydroxyethylene dipeptide isosteres using novel, chiral aminoalkyl epoxides and .gamma.-(aminoalkyl)-.gamma.-lactones , 1985 .

[80]  E A Emini,et al.  Benzocycloalkyl amines as novel C-termini for HIV protease inhibitors. , 1991, Journal of medicinal chemistry.

[81]  Narmada Thanki,et al.  Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling , 1992, Protein science : a publication of the Protein Society.

[82]  P. Reider.  Advances in AIDS Chemotherapy: The Asymmetric Synthesis of CRIXIVAN® , 1997, CHIMIA.

[83]  T. Bhat,et al.  Symmetry-based HIV Protease inhibitors: rational design of 2-methylbenzamides as novel P2/P2′ ligands , 1995 .

[84]  S. Carr,et al.  Human immunodeficiency virus-1 protease. 1. Initial velocity studies and kinetic characterization of reaction intermediates by 18O isotope exchange. , 1991, Biochemistry.

[85]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[86]  A M Hassell,et al.  Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. , 1992, Biochemistry.

[87]  E D Blair,et al.  Human Immunodeficiency Virus , 1996, The Journal of Biological Chemistry.